A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked ...

Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...

Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.

DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last ...

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz.

Dexcom, a medical device manufacturer that develops continuous glucose monitoring systems, received a warning letter from the FDA regarding manufacturing processes at its facilities in San Diego and ...

Shares of DexCom Inc. slipped 9.15% to $70.72 Monday, on what proved to be an all-around poor trading session for the stock ...